secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0001689548-25-000062
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Precision reports sustained seizure reduction with relutrigine, announces Phase 3 trial design
--------------------------------------------------------------------------------

- Updated EMBOLD open-label data (n=12) show sustained seizure reduction and increased seizure-free periods through 11 months of relutrigine treatment in SCN2A/SCN8A DEEs.
- Announced EMERALD Phase 3 trial design: randomized, placebo-controlled, 160 patients aged 2–65 years, 16-week treatment period.
- Plans to nominate development candidate for PRAX-100, an antisense oligonucleotide targeting SCN2A loss-of-function in autism, in mid-2025.
- Corporate presentation furnished as Exhibit 99.1 includes program updates provided at May 2, 2025 investor event.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000062/0001689548-25-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000062/prax-20250502.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer